Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Sayed Mehdi Hamadani, MD, Thomas Samith Kochuparambil, Salman Osman, MD, Ethan Speir, Michael Craig, MD, David Deremer, Aaron Cumpston, PharmD, Devi D Morrison, Sonia Leadmon, BS, Kristen Sterling, Pamela Bunner, BS, Meghan Sterrett, Vamsi Kota, MBBS, Anand P. Jillella, MD, Farrukh T Awan, MD, MS

Blood (2011) 118 (21): 313.

https://doi.org/10.1182/blood.V118.21.313.313

Published: 2011

Journal Articles

Clofarabine In Combination with Cyclophosphamide for Treatment of Relapsed/Refractory Acute Leukemia In Adult Patients

Bobby Chawla, DO, Abraham Sebastian Kanate, MD, Salman Osman, MD, William Tse, MD, Sayed Mehdi Hamadani, MD, Michael Craig, MD, Aaron Cumpston, PharmD

Blood (2010) 116 (21): 4367.

https://doi.org/10.1182/blood.V116.21.4367.4367

Published: 2010

Journal Articles

In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant.

Abraham S Kanate, MD, Salman Osman, MD, Aaron Cumpston, PharmD, Gerry Hobbs, PhD, Sonia Leadmon, BS, Pamela Bunner, BS, Laura Gibson, PhD, William Tse, MD, Jame Abraham, MD, FACP, Scot Remick, MD, FACP, Michael Craig, MD, Sayed Mehdi Hamadani, MD

Blood (2010) 116 (21): 4536.

https://doi.org/10.1182/blood.V116.21.4536.4536

Published: 2010

Journal Articles

Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Salman Osman, MD, Abraham Sebastian Kanate, MD, Pamela Bunner, BS, Sonia Leadmon, BS, William Tse, Aaron Cumpston, PharmD, Laura Gibson, PhD, Scot Remick, MD, FACP, Jame Abraham, MD, FACP, Michael Craig, MD, Sayed Mehdi Hamadani, MD

Blood (2010) 116 (21): 1347.

https://doi.org/10.1182/blood.V116.21.1347.1347

Published: 2010

Journal Articles

Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes of Multiple Myeloma Patients Undergoing Autologous Transplantation – A Multicenter Analysis

Farrukh Awan, MD, MS, Salman Osman, MD, Samith Thomas Kochuparambil, Scot Remick, MD, FACP, Jame Abraham, MD, FACP, Michael Craig, MD, Anand P. Jillella, MD, Sayed Mehdi Hamadani, MD

Blood (2010) 116 (21): 1351.

https://doi.org/10.1182/blood.V116.21.1351.1351

Published: 2010

Journal Articles

Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant

Abraham S Kanate, MD, Salman Osman, MD, Aaron Cumpston, PharmD, Gerry Hobbs, PhD, Sonia Leadmon, BS, Pamela Bunner, BS, Kathy Watkins, MT, Laura Gibson, PhD, William Tse, MD, Jame Abraham, MD, FACP, Scot Remick, MD, FACP, Michael Craig, MD, Sayed Mehdi Hamadani, MD

Blood (2010) 116 (21): 1272.

https://doi.org/10.1182/blood.V116.21.1272.1272

Published: 2010

NARROW

Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Clofarabine In Combination with Cyclophosphamide for Treatment of Relapsed/Refractory Acute Leukemia In Adult Patients

In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant.

Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes of Multiple Myeloma Patients Undergoing Autologous Transplantation – A Multicenter Analysis

Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies – A Multicenter Analysis

Clofarabine In Combination with Cyclophosphamide for Treatment of Relapsed/Refractory Acute Leukemia In Adult Patients

In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant.

Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes of Multiple Myeloma Patients Undergoing Autologous Transplantation – A Multicenter Analysis

Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only